Arvinas reports positive PRO data from Phase 3 VERITAC-2 for vepdegestrant in ESR1-mutated breast cancer

ARVINAS, INC.

Vepdegestrant showed reduced risk of deterioration vs fulvestrant in overall health status, pain severity, and functioning domains; statistically significant.
PRO data presented at ESMO 2025 support vepdegestrant as potential best-in-class therapy for ESR1-mutated ER+/HER2- metastatic breast cancer.
Also presented TACTIVE-N Phase 2 results: neoadjuvant vepdegestrant demonstrated biological and clinical activity in localized breast cancer.
Vepdegestrant is a PROTAC ER degrader developed with Pfizer; previously reported statistically significant PFS improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.